Total Payments
$2,650
2024 Payments
$769.74
Companies
44
Transactions
135
Medicare Patients
2,272
Medicare Billing
$207,785
Payment Breakdown by Category
Food & Beverage$2,498 (94.3%)
Education$151.47 (5.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,498 | 131 | 94.3% |
| Education | $151.47 | 4 | 5.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $393.86 | 19 | $0 (2024) |
| Janssen Biotech, Inc. | $191.01 | 8 | $0 (2024) |
| Merck Sharp & Dohme LLC | $175.45 | 8 | $0 (2024) |
| Celgene Corporation | $160.41 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $147.87 | 8 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $139.17 | 9 | $0 (2024) |
| PFIZER INC. | $115.21 | 6 | $0 (2024) |
| Amgen Inc. | $109.34 | 8 | $0 (2023) |
| Genentech USA, Inc. | $108.10 | 7 | $0 (2024) |
| Gilead Sciences, Inc. | $96.02 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $769.74 | 36 | Novartis Pharmaceuticals Corporation ($86.52) |
| 2023 | $572.29 | 29 | Celgene Corporation ($83.45) |
| 2022 | $158.48 | 9 | Novartis Pharmaceuticals Corporation ($43.85) |
| 2021 | $91.75 | 6 | Novartis Pharmaceuticals Corporation ($54.86) |
| 2020 | $103.55 | 3 | Astellas Pharma US Inc ($64.99) |
| 2019 | $236.11 | 15 | Amgen Inc. ($38.85) |
| 2018 | $339.38 | 16 | Puma Biotechnology, Inc. ($57.09) |
| 2017 | $378.35 | 21 | Janssen Biotech, Inc. ($105.35) |
All Payment Transactions
135 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Oncology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.28 | General |
| 12/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo, Tecentriq | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: BioOncology | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $31.57 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Oncology | ||||||
| 10/10/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.69 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $32.35 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.13 | General |
| 07/18/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Oncology | ||||||
| 06/28/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: Oncology | ||||||
| 06/20/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Oncology | ||||||
| 06/18/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: NONE | ||||||
| 06/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Oncology | ||||||
| 06/04/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.26 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $18.00 | General |
| 05/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| Category: Hematology | ||||||
| 05/02/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $24.13 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 354 | 689 | $112,989 | $31,957 |
| 2022 | 4 | 443 | 931 | $161,570 | $48,171 |
| 2021 | 7 | 555 | 1,114 | $189,866 | $58,597 |
| 2020 | 6 | 920 | 1,485 | $229,570 | $69,060 |
Total Patients
2,272
Total Services
4,219
Medicare Billing
$207,785
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 212 | 445 | $68,012 | $19,002 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 148 | $32,429 | $10,041 | 31.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 38 | 54 | $5,372 | $1,084 | 20.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 30 | $4,560 | $1,012 | 22.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 12 | $2,616 | $817.84 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 126 | 334 | $72,812 | $23,233 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 248 | 480 | $72,960 | $20,574 | 28.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 54 | 102 | $10,098 | $2,613 | 25.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $5,700 | $1,751 | 30.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 302 | 580 | $88,160 | $26,192 | 29.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 134 | 342 | $74,556 | $24,291 | 32.6% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 71 | 124 | $12,276 | $3,125 | 25.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $4,560 | $1,727 | 37.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 12 | 14 | $4,431 | $1,472 | 33.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 23 | $3,793 | $1,224 | 32.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 11 | 19 | $2,090 | $565.82 | 27.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 313 | 545 | $74,020 | $18,366 | 24.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 111 | 221 | $43,355 | $12,749 | 29.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 177 | 214 | $32,528 | $11,891 | 36.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 79 | 129 | $28,122 | $10,836 | 38.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 26 | 26 | $9,906 | $3,321 | 33.5% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 103 | 169 | $14,729 | $2,842 | 19.3% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 57 | 74 | $7,326 | $2,484 | 33.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 17 | 22 | $6,892 | $2,378 | 34.5% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 24 | 72 | $7,752 | $2,234 | 28.8% |
About Dr. Michael Pavy, MD
Dr. Michael Pavy, MD is a Hematology & Oncology healthcare provider based in Florence, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568405371.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Pavy, MD has received a total of $2,650 in payments from pharmaceutical and medical device companies, with $769.74 received in 2024. These payments were reported across 135 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($2,498).
As a Medicare-enrolled provider, Pavy has provided services to 2,272 Medicare beneficiaries, totaling 4,219 services with total Medicare billing of $207,785. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Florence, SC
- Active Since 06/13/2006
- Last Updated 01/03/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1568405371
Products in Payments
- KISQALI (Drug) $196.85
- KEYTRUDA (Biological) $146.95
- IMBRUVICA (Drug) $91.17
- Pomalyst (Drug) $88.96
- PIQRAY (Drug) $58.37
- Nerlynx (Drug) $57.09
- OPDIVO (Biological) $55.08
- Revlimid (Drug) $42.09
- CALQUENCE (Drug) $41.48
- ERLEADA (Drug) $41.17
- INLYTA (Drug) $38.18
- LYNPARZA (Drug) $37.09
- Nubeqa (Drug) $36.67
- CYRAMZA (Drug) $36.04
- OJJAARA (Drug) $35.73
- IMFINZI (Drug) $35.68
- TUKYSA (Drug) $34.65
- OPDUALAG (Drug) $33.39
- ALUNBRIG (Drug) $32.35
- PADCEV (Biological) $32.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Florence
Dr. Mark Keaton, M.d, M.D
Hematology & Oncology — Payments: $30,744
Hematology & Oncology $30,744
Dr. Clint Kingsley, Md, MD
Hematology & Oncology — Payments: $21,594
Hematology & Oncology $21,594
Rajesh Bajaj, M.d, M.D
Hematology & Oncology — Payments: $18,826
Hematology & Oncology $18,826
Dr. Heather Brody
Hematology & Oncology — Payments: $10,048
Hematology & Oncology $10,048
Ravneet Bajwa, M.d, M.D
Hematology & Oncology — Payments: $4,477
Hematology & Oncology $4,477
Dr. Anthony Kalliath, Md, MD
Hematology & Oncology — Payments: $2,727
Hematology & Oncology $2,727